(Q30486336)

18 August 2017

ARC (NSC 188491) has identical activity to Sangivamycin (NSC 65346) including inhibition of both P-TEFb and PKC. (English)

1 reference

18 August 2017

Luke H Stockwin

1

1 reference

18 August 2017

Sherry X Yu

2

1 reference

18 August 2017

Howard Stotler

3

1 reference

18 August 2017

Melinda G Hollingshead

4

1 reference

18 August 2017

Dianne L Newton

5

1 reference

18 August 2017

language of work or name

English

0 references

publication date

20 February 2009

1 reference

18 August 2017

1 reference

18 August 2017

9

1 reference

18 August 2017

63

1 reference

https://scigraph.springernature.com/pub.10.1186/1471-2407-9-63

18 August 2017

0 references

cites work

Protein kinase C alpha promotes angiogenic activity of human endothelial cells via induction of vascular endothelial growth factor.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2651907

Differential sensitivity of human colon cancer cell lines to the nucleoside analogs ARC and DRB.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2651907

Inhibition of tumor angiogenesis by targeting endothelial surface ATP synthase with sangivamycin

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2651907

The therapeutic role of targeting protein kinase C in solid and hematologic malignancies

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2651907

Proapoptotic compound ARC targets Akt and N-myc in neuroblastoma cells.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2651907

The nucleoside analog sangivamycin induces apoptotic cell death in breast carcinoma MCF7/adriamycin-resistant cells via protein kinase Cdelta and JNK activation

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2651907

A novel anticancer agent ARC antagonizes HIV-1 and HCV.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2651907

Purine nucleoside analogs as immunosuppressive and antineoplastic agents: mechanism of action and clinical activity

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2651907

Protein kinase C as a therapeutic target

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2651907

A novel transcriptional inhibitor induces apoptosis in tumor cells and exhibits antiangiogenic activity.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2651907

Cellular and clinical pharmacology of fludarabine

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2651907

Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2651907

Requirement for p53 and p21 to sustain G2 arrest after DNA damage

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2651907

Synthetic hispidin, a PKC inhibitor, is more cytotoxic toward cancer cells than normal cells in vitro

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2651907

In vivo cultivation of tumor cells in hollow fibers

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2651907

Purine analogs and related nucleosides and nucleotides as antitumor agents

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2651907

Sangivamycin, a nucleoside analogue, is a potent inhibitor of protein kinase C.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2651907

Preclinical antitumor activity of an alpha-picoline derivative, penclomedine (NSC 338720), on human and murine tumors.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2651907

Selective growth inhibition by sangivamycin of human umbilical vein endothelial cells.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2651907

Pyrrolo[2,3-d]pyrimidine nucleoside antibiotics. Total synthesis and structure of toyocamycin, unamycin B, vengicide, antibiotic E-212, and sangivamycin (BA-90912)

26 November 2018

1 reference

12 December 2020

Initial toxicity study of sangivamycin (NSC-65346)

1 reference

12 December 2020

Nucleoside analogs in the treatment of neoplastic and nonneoplastic diseases

1 reference

12 December 2020

Comparison of the cellular and RNA-dependent effects of sangivamycin and toyocamycin in human colon carcinoma cells

1 reference

12 December 2020

A new biological role of sangivamycin; inhibition of protein kinases

1 reference

12 December 2020

Lasting remissions in hairy-cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine

1 reference

12 December 2020

Action of 9-beta-D-arabinofuranosyl-2-fluoroadenine on RNA metabolism

1 reference

12 December 2020

Toyocamycin, a new anti-candida antibiotics.

1 reference

12 December 2020

Structure of sangivamycin

1 reference

12 December 2020

Identifiers

DOI

10.1186/1471-2407-9-63

1 reference

Dimensions Publication ID

18 August 2017

0 references

1 reference

18 August 2017

1 reference